Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.

NCT00076089 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00076089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00076089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2003
Completion date
December 31, 2005
Enrollment
1,100
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease, copd